Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
This specific subset of stent grafts has greater susceptibility to fabric permeability variations that may be associated with endoleaks observed during the initial implant procedure. at the time of implant procedure this permeability variation may cause the physician to categorize a type iv endoleak (which typically self-resolves over time) as an acute type ill fabric endoleak because the leak may appear to be focal or a localized leak as opposed to a diffused leak (blush). the misclassification as an acute type ill fabric endoleak may lead to unnecessary secondary interventions.
Model Catalog: ETBF2516C166EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2516C145EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2516C124EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2513C166EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2513C145EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2313C124EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2316C166EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2316C145EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2316C124EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2313C166EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2313C145EE (Lot serial: >10 lot numbers contact mfg); Model Catalog: ETBF2513C124EE (Lot serial: >10 lot numbers contact mfg)
“If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.